Daiichi Sankyo and Merck withdraw BLA for patritumab deruxtecan in US
The decision comes after examining overall survival results from the HERTHENA-Lung02 Phase 3 trial, which failed to achieve statistical significance, in conjunction with talks with the FDA

Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry